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Background: Identification of effective treatments in severe cases of COVID-19 requiring mechanical ventila-
tion represents an unmet medical need. Our aim was to determine whether the administration of adipose-
tissue derived mesenchymal stromal cells (AT-MSC) is safe and potentially useful in these patients.
Methods: Thirteen COVID-19 adult patients under invasive mechanical ventilation who had received previous
antiviral and/or anti-inflammatory treatments (including steroids, lopinavir/ritonavir, hydroxychloroquine
and/or tocilizumab, among others) were treated with allogeneic AT-MSC. Ten patients received two doses,
with the second dose administered a median of 3 days (interquartile range-IQR- 1 day) after the first one.
Two patients received a single dose and another patient received 3 doses. Median number of cells per dose
was 0.98 £ 106 (IQR 0.50 £ 106) AT-MSC/kg of recipient’s body weight. Potential adverse effects related to
cell infusion and clinical outcome were assessed. Additional parameters analyzed included changes in imag-
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2 F. Sanchez-Guijo et al. / EClinicalMedicine 25 (2020) 100454Findings: First dose of AT-MSC was administered at a median of 7 days (IQR 12 days) after mechanical ventila-
tion. No adverse events were related to cell therapy. With a median follow-up of 16 days (IQR 9 days) after
the first dose, clinical improvement was observed in nine patients (70%). Seven patients were extubated and
discharged from ICU while four patients remained intubated (two with an improvement in their ventilatory
and radiological parameters and two in stable condition). Two patients died (one due to massive gastrointes-
tinal bleeding unrelated to MSC therapy). Treatment with AT-MSC was followed by a decrease in inflamma-
tory parameters (reduction in C-reactive protein, IL-6, ferritin, LDH and D-dimer) as well as an increase in
lymphocytes, particularly in those patients with clinical improvement.
Interpretation: Treatment with intravenous administration of AT-MSC in 13 severe COVID-19 pneumonia
under mechanical ventilation in a small case series did not induce significant adverse events and was fol-
lowed by clinical and biological improvement in most subjects.
Funding: None.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Case series1. Introduction
The current SARS-CoV-2 pandemic has stretched the capacity of
the health systems in many of the affected countries to the limit, con-
ditioned by the need for intensive care in many of these patients [1].
Patients admitted to the Intensive Care Unit (ICU) requiring mechani-
cal ventilation show significant mortality that ranges between 30 and
60% [24]. Factors that have been associated with a worse prognosis
in patients with severe SARS-CoV-2 pneumonia include age over
65 years, the existence of comorbidities as diabetes, male gender, and
elevated levels of C-reactive protein or lactate dehydrogenase (LDH),
among others [58]. Even, in those patients with a favorableon allogeneic mes-
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eady under way.outcome, an additional problem that contributes to the ICU satura-
tion, is the long average stay under invasive mechanical ventilation
[9]. Therefore, any adjuvant treatment that contributes to accelerate
the recovery will represent a major step forward.
One of the most striking facts of the physiopathology of pneumo-
nia in COVID-19 disease [10] is the development of a massive inflam-
matory phase [11,12], with elevation of numerous acute phase
reactants and cytokines (e.g. ferritin, C-reactive protein, fibrinogen,
LDH or IL-6), leading to acute respiratory distress syndrome (ARDS)
and macrophage activation syndrome (MAS)-like disease [13,14]. In
addition, the presence of a progressive endothelial thrombo-inflam-
matory syndrome (with elevated D-dimer) not described in other
viral infections adds differential features and aggravates the disease's
prognosis [1517]. This inflammatory reaction underlies the ratio-
nale for the development of clinical trials evaluating the role of drugs
with anti-inflammatory activity, such as tocilizumab, anakinra, sil-
tuximab, and others [1820].
Among the potential therapeutic options to reduce this clinical
and biological picture of massive inflammation the use of mesenchy-
mal stromal cells (MSCs) is generating increasing interest. Neverthe-
less, to date, information published on critically ill patients
undergoing mechanical ventilation treated with MSC is reduced to a
single reported case [21]. However, more than 17 clinical trials are
registered in ClinicalTrials.gov to evaluate the role of mesenchymal
cells from different sources [22]. MSC have been approved for the
treatment of Crohn's disease or graft-versus-host disease after
hematopoietic transplantation [23] based in their anti-inflammatory
and immunomodulatory effects thus suggesting that adipose tissue-
derived MSCs (AT-MSCs) could be an attractive therapeutic option
for the treatment of severe SARS-CoV-2 pneumonia [24].
In the current report we describe the outcome of a group of 13
patients with severe SARS-CoV-2 pneumonia requiring mechanical ven-
tilation, who had not responded to previous antiviral and anti-inflam-
matory treatments (including in some cases tocilizumab, steroids,
anakinra and/or siltuximab), and who were treated with AT-MSCs on a
compassionate-use basis. These results represent the preliminary expe-
rience of four academic centers of the Spanish National Cell Therapy
Network (TerCel) [25] and establishes the basis for the current phase 2
randomized controlled clinical trial (BALMYS-19 (“BAttLe against CO
using MesenchYmal Stromal cells; EudraCT: 2020-001266-11; clinical-
trials.gov identifier NCT04348461) already in progress.2. Methods
2.1. Patients
Patients with SARS-CoV-2 infection confirmed by reverse-tran-
scriptase-polymerase-chain-reaction assay and COVID-associated
pneumonia diagnosed by either chest X-ray or computed tomogra-
phy and requiring mechanical ventilation in the ICU and in
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the study: 1) tachypnea (RR  30 times / min), 2) finger oxygen satu-
ration  93% in resting state, 3) arterial oxygen partial pressure
(PaO2) / fraction of inspired oxygen (FiO2)  300 mmHg, 4) pulmo-
nary imaging with evidence of progression > 50% in 2448 h and a
Sequential Organ Failure Assessment (SOFA) score [26] >3 points,
World Health Organization (WHO) Ordinal Scale for Clinical Improve-
ment [27] level 6 and no evidence of multiorgan failure. Additional
inclusion criteria included age older than 18 years, a creatinine clear-
ance above 30 ml per minute and serum levels of alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) less than five times
the upper limit of the normal range (40 units/liter). Patients with
active neoplasms or with systemic immunosuppressive treatments
prior to admission were excluded from this program. All patients
were treated at four different Spanish academic hospitals that are
members of the Spanish Cell Therapy Network (TerCel) [25] and had
the experience and infrastructure to administer allogeneic MSC: Hos-
pital Universitario de Salamanca, Fundacion Jimenez Diaz, Hospital
Universitario Gregorio Mara~non and Clínica Universidad de Navarra.
Treatment with AT-MSC was approved by The Spanish Medicines
Agency (AEMPS, https://www.aemps.gob.es/) as part of a compas-
sionate use program after informed consent from the patients' rela-
tives was obtained.
2.2. Cell treatment
AT-MSC were obtained by liposuction from voluntary donors per-
formed by surgeons from the Plastic Surgery Departments of the par-
ticipating hospitals. In all cases, donors were young (less than 50
years) with no comorbidities or concomitant treatments. The analyti-
cal and serological studies required by the legislation on cell and tis-
sue donation in the European Union and in Spain were obtained in
each case, as well as specific informed consent to use the cells for
clinical application.
Cell production was carried out in the Good Manufacturing Practi-
ces (GMP) Facilities of the Hospital Universitario de Salamanca,
Clínica Universidad de Navarra and Hospital Gregorio Mara~non in
accordance with the investigational Medicinal Product Dossier
(IMPD) with reference code PEI-15103, approved by the Spanish
Medicines Agency (AEMPS). Briefly, 100 ml of lipoaspirate (corre-
sponding to 50 g of fat tissue) were obtained from each donor. Sam-
ples were digested with collagenase and further expanded in the
GMP facilities in standard conditions, as previously reported [28,29].
Cells were cryopreserved in bags containing from 50 to 75 £ 106
MSC. In all cases, less than 20 population doublings and less than 2
passages were performed before administration. Characterization of
the final product included the International Society for Cellular Ther-
apy (ISCT) definition criteria with morphology, immunophenotypic
profile, multi-lineage differentiation ability [30]. In addition, compar-
ative genomic hybridization arrays to ensure genomic stability and a
potency test evaluating the inhibition of the proliferation of activated
T-lymphocytes were performed.
Cell were cryopreserved and stored until use. Cell viability was
tested only before cryopreservation. Cryopreserved cells were
administered immediately after thawing in a medium containing AB
serum and 10% dimethyl sulfoxide without washing at the Hospital
Universitario de Salamanca and Clinica Universidad de Navarra, while
the remaining centers used "refreshed" cells that were seeded back
onto plastic surface for a period of less than 72 h and then trypsinized
and resuspended in a solution of Ringer’s lactate with 1% albumin
before administration, that in all cases were infused in less than 24 h
from harvesting. In the first case, steroids and dexchlorpheniramine
were administered prior to cell infusion. In every case, administration
was performed intravenously by personnel experienced in the use of
AT-MSCs using a standard 200-micron transfusion filter at a target
dose of 1 £ 106 AT-MSCs/kg of recipient’s body weight. Treatedsubjects received cells from five different donors, although each indi-
vidual patient received cells from the same cell product batch. In this
compassionate use program, patients received a first dose of AT-
MSCs (day 1) and were scheduled for a second dose if deemed clini-
cally appropriate by the treating physician, between 48 and 96 h
later. This was based on previous literature, clinical course and on the
putative mechanism of action [3133]. Eventually, a third dose was
allowed to be administered. Supportive therapy included, in addition
to mechanical ventilation and sedation, the use of vasopressor or ino-
tropic drugs, enteral or parenteral nutrition, antibiotics and/or diu-
retics, among other standard procedures, and was provided at the
discretion of the clinicians until discharge from ICU or death.2.3. Study assessments
In each patient, toxicity and potential adverse events related to
cell administration were recorded. All intubated patients in the ICU
were continuously monitored with electrocardiography, continuous
invasive blood pressure, pulse oximetry and capnography to immedi-
ately detect any potential adverse reaction during the infusion of cells
and afterwards. Ventilatory, radiological and analytical parameters
including complete blood counts (CBC) and basic biochemistry, coag-
ulation (including fibrinogen and D-dimer) and acute phase reactants
(C-reactive protein, ferritin, LDH and/or IL-6) were obtained before
the first dose of AT-MSCs (routinely in the morning of the same day),
and daily for 5 days and at regular intervals thereafter depending on
clinical or institutional criteria. Specifically, most centers performed
CBC, biochemistry and coagulation daily in ICU, and chest-X rays, fer-
ritin or IL-6 every 510 days after the first 57 days, and when clini-
cally appropriate. Chest X-rays were evaluated by two independent
observers according to the score proposed by Wong et al. [34].
Although there were no pre-specified end points for this compassion-
ate-use program, we registered and quantified prospectively the inci-
dence of potential adverse events, as previously indicated, through
continuous monitoring while in ICU. In addition, we evaluated the
proportion of patients with clinical improvement, as defined by extu-
bation, discharge from ICU, radiographic improvement or at least
one-point decrease in the World Health Organization (WHO and R&D
Blueprint Group Ordinal Scale for Clinical Improvement) [27]. The
appearance of respiratory or other concomitant infections was also
collected, as well as any concomitant medications administered from
date of hospital admission. Main lymphocyte subpopulations in
peripheral blood (B cells, CD4+ T cells, CD8+ T cells, NK cells) were
quantified before and 10 days after AT-MSCs administration. The
length of time from admission to the start of mechanical ventilation,
the time between mechanical ventilation and the first AT-MSC
administration, and the time between the latter and extubation or
death were also analyzed.2.4. Statistical analysis
All data were stored in and Excel file (Microsoft, Redmond, Wash-
ington) and then imported into the SPSS.v25 (IBM, Armonk, New
York) statistical package. Tables and Fig. 1 were performed with Excel
(Microsoft) and GraphPad.v8 (GraphPad software, San Diego, Califor-
nia) was used to create the graphic that compose Fig. 2. Median and
interquartile ranges (IQRs) were calculated for quantitative variables.2.5. Role of funding
Funding source: none. Fermin Sanchez-Guijo had full access to all
the data in the study and had final responsibility for the decision to
submit for publication.
Fig. 1. Patient disposition and outcome.
Patient evolution is indicated in separate rows, with the same number and order shown in Table 1. Mesenchymal stromal cell (MSC) doses and timing are represented in arrows.
In the X axis, days from the first MSC dose are specified. Type of ventilation support is graded in colors through each row. Main complications (infectious complications or bleeding)
are included in each row when appropriate. Green and red circles designate those patients with favorable or stable evolution at last day of follow-up. Finally, black or white dia-
monds denote final outcome, dead or hospital discharge, respectively. Abbreviations. MSC: mesenchymal stromal cells; ICU: Intensive care unit; ECMO: extracorporeal membrane
oxygenation; GI: gastrointestinal.
Fig. 2. Chest X-ray changes of two representative patients improving after AT-MSC
administration.
A (before) and B (48 h after) cell infusion.
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3.1. Patient and baseline characteristics
Thirteen patients were treated with AT-MSC between April 3rd and
April 22nd, 2020. In two cases, a single dose was administered, one
patient received 3 doses and the remaining ten patients received 2 doses,the second administered at a median of 3 days (IQR 1 day) after the first
one. More specifically, the two patients that received a single dose did
improve significantly after administration of the AT-MSC and no need for
additional doses was deemed necessary. On the other hand, in one
patient, although improvement was observed after the first 2 doses,
worsening of his condition and availability of an additional cell dose was
considered as a reason for an additional administration of cells. Median
number of AT-MSCs per dose was 0.98 (IQR 0.5) x 106 /kg. In 7 patients,
cells were reseeded and refreshed for 72 h while in the remaining 6
patients AT-MSCswere directly thawed and immediately infused intrave-
nously. Baseline and treatment characteristics of the patients are summa-
rized in Table 1. Median age was 60 years (IQR 11 years). Twelve of the
13 patients were male. All patients were under invasive mechanical ven-
tilation at baseline (before the first MSC administration). Median time
from Hospital admission to mechanical ventilation was 4 days (IQR 3
days) and the median duration of invasive mechanical ventilation before
the first dose of AT-MSC was 7 days (IQR 12 days). All patients received
corticosteroids, prophylactic antibiotics (mainly ceftriaxone) and low-
molecular weight heparin. Eleven of 13 patients (85%) had received
hydroxychloroquine (7 in combination with azithromycin), and the same
percentage had received tocilizumab. Anakinra was given in 2 patients
(15%), one after tocilizumab, whereas siltuximab was additionally admin-
istered after tocilizumab and anakinra in one patient. Finally, lopinavir/
ritonavir was also administered in 11 patients (85%). At the time of cell
administration only steroids were administered concomitantly. Most
patients received supportive treatment during their ICU stay. This
included, in addition to mechanical ventilation and sedation, the use of
vasopressor or inotropic drugs, enteral or parenteral nutrition, antibiotics
and/or diuretics, among other standard procedures.3.2. Safety
No adverse events were associated with the infusion of AT-MSC
including fever orworsening of respiratory or hemodynamic
Table 1
Patient baseline characteristics and treatments.
Patients
1 2 3 4 5 6 7 8 9 10 11 12 13
Age (years) 55 64 68 55 47 62 63 62 50 59 55 71 73
Gender M M F M M M M M M M M M M
Ethnicity Caucasian Caucasian Caucasian Caucasian Cauc-
asian
Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian
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Smoking No No No Ex- smoker No Ex -smoker Ex -smoker No No No Ex -smoker Ex -smoker No
Laboratory
IL-6 1000 238 87.2 7.8 82.3 92.8 209 NT NT NT 195.4 206.6 13.7
CRP 2.21 1.90 3.67 10.80 0.50 0.70 13.10 9.10 26.80 34.00 3.71 0.60 3.60
Ferritin 1062 3194 401 3592 1095 3603 2400 NT 2155 1602 1401 531 5428
D-dimer 25,000 1865 970 2980 1821 7500 6352 6400 3456 852 1690 1750 1766
Fibrinogen 213 176 699 788 287 90 630 640 896 793 426 226 622
Hb 14.6 11 9.9 12.8 11.4 12.8 14.9 13.7 9.2 9.4 8.9 10.2 14.7
Platelets 215 210 429 221 134 131 297 449 224 158 170 138 349
Lymphocytes 1.98 0.5 1.16 0.46 0.50 0.46 0.30 0.40 0.40 0.40 0.70 0.71 0.30
LDH 519 308 543 774 299 1453 530 677 239 187 305 316 777
SOFA score before
AT-MSC infusion





2 £ 400mg 1 £ 400mg 1 £ 600mg No 1 £ 400mg 1 £ 400mg 2 £ 600mg 1 £ 600mg 1 £ 600mg No 1 £ 600mg 1 £ 600 mg
1 £ 400mg
1 £ 400mg
Anakinra No No No No No 1 £ 100mg No No No 1 £ 100mg No No No
Siltuximab No No No No No 1 £ 800mg No No NO No No No No
Hydroxychloroquine Yes Yes Yes Yes No Yes Yes Yes Yes No Yes Yes Yes
Lopinavir/Ritonavir Yes Yes Yes Yes No Yes Yes Yes Yes No Yes Yes Yes
Steroids Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
AT-MSC, No. doses 2 1 2 3 2 2 1 2 2 2 2 2 2
Days in ICU with
mechanical ventilation
after AT-MSC infusion
14 16 2 19 23 7 3 16 11 11 2 11 4
Days in ICU without
mechanical ventilation
after AT-MSC infusion
10 6 6 2 0 2 4 0 0 0 10 0 0
M: male; F: female; BMI: Body Mass Index (kg/m2); HBV: Hepatitis B virus; COPD: Chronic Obstructive Pulmonary Disease; IL-6: Interleukin-6 (pg/mL); CRP: C-reactive protein (mg/dL); Ferritin (mg/dL), D-dimer: ng/mcL; Fibrinogen (mg/dL),










Fig. 3. (A) Changes in acute phase reactants and coagulation parameters after AT-MSC therapy.
Values of each parameter are indicated by dots joined by a color line before adipose tissue derived mesenchymal stromal cell therapy and at day five from the first dose for each
individual and evaluable patient. Green or red colors represent patients with favorable or unfavorable evolution (stable or death), according to the color codes of Fig. 1.
(B) Changes in lymphocyte counts and lymphocyte subsets after AT-MSC therapy.
Values of each cell population are indicated by dots joined by a color line before adipose tissue derived mesenchymal stromal cell therapy and at day ten from the first dose for
each individual and evaluable patient. Green color represents patients with favorable evolution, according to the color codes of Fig. 1.
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dia 24 h after cell administration despite treatment with steroids and
dexchlorpheniramine. Subsequently, a severe decrease in hemoglo-
bin was observed. A CT scan and upper gastrointestinal endoscopy
were performed showing massive digestive bleeding due to a gastric
ulcer, whose location coincided with the position of the nasogastric
tube. Despite intensive supportive therapy, the patient died. In light
of this information, this early complication was deemed not to be
related to cell administration.
No significant changes in physiological parameters measured by
continuous monitoring were observed immediately after AT-MSC
infusion, nor in the biological parameters (including coagulation,
hepatic, cardiac or renal function) performed daily after cell adminis-
tration (Supplementary Table 1).
3.3. Clinical and radiological improvement
After a median follow-up of 16 days (IQR 9 days) after the first dose
of AT-MSCs, 9 patients (70%) had improved clinically and 7 (53%) were
extubated (Fig. 1) with a median time from the first MSC dose to extu-
bation of 7 days (IQR 14 days). In two patients, extracorporeal mechani-
cal oxygenation (ECMO) was required but both remain stable at the
time of writing this report, 11 and 23 days after the first cell dose. Two
patients died, one from massive gastrointestinal bleeding (described
before) and another one from secondary fungal pneumonia by Saccharo-
myces spp. One patient developed a concurrent respiratory pneumonia
due to a methicillin-resistant Staphylococcus aureus and one patient
developed a fungal infection by Candida spp. However, they subse-
quently improved after appropriate antibacterial and antifungal therapy
according to the respective antibiogram and antifungigram and werethen extubated. Radiological improvement in sequential X-rays was
confirmed after AT-MSC administration (in the quantitative scale previ-
ously described [34]) in 40% of evaluable patients (Fig. 2). For radiologi-
cal evaluation we considered 10 evaluable patients, excluding the
patient who died early 24 h after cell administration and the two
patients with concomitant fungal infection at the time of cell infusion.
When we examined the time from intubation to administration of
AT-MSC, we observed that patient successfully extubated had
received the cells earlier than patients that were not extubated
(median 5 days, IQR: 11 days versus 10 days, IQR: 15 days).
3.4. Laboratory response and immune monitoring
For laboratory evaluation, the patient who died prematurely and the
patient who was on ECMO before day +5 (after the first AT-MSC dose)
was excluded from the analysis. An additional patient was not evaluable
for ferritin and IL-6 as these analyses were not performed on the fifth
day after cell infusion. When we analyzed the nine patients that
improved clinically (according to Fig. 1), a decrease in inflammatory
parameters associatedwith AT-MSC therapywas observed at day 5 after
infusion (Fig. 3A) with a decrease in C-reactive protein in 8 patients
(88%), LDH in 9 (100%), and D-dimer and ferritin in 5 of 8 evaluable
patients (63%), since one responding patient did not have the results of
both parameters at day +5 after the first AT-MSC dose. In six patients in
which lymphocyte counts were measured by flow cytometry, an
increase in the levels of total lymphocytes was observed in five of them
(86%), as well as an increase in B- (67%) and CD4+ and CD8+ (100%) T
lymphocytes (Fig. 3B). Lymphocyte subset analysis was available in six
patients that improved after MSC therapy, but no information on non-
responding as well as in 3 responding patients was available.
Fig. 3 Continued.
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The severity of the COVID-19 pandemic and the lack of effective
proven therapies represents a formidable challenge and have stimulated
multiple research groups on an urgent search for potentially useful ther-
apeutic options [1820]. Multiple clinical trials are currently underway
with a wide range of drugs (in the https://clinicaltrials.gov/hclinical
trials.gov website accessed on May 1st are registered up to 600 clinical
trials, almost half of which are already under recruitment). Furthermore,
due to the therapeutic urgency many treatments are being used off-
label through compassionate use programs [35]. Here, we report the
first series of COVID-19 patients requiring mechanical ventilation
treated with AT-MSC, generating preliminary evidence of the absence of
significant adverse events along with improvement in most of these
patients. These results warrant conducting a multicenter randomized
controlled trial already underway.
The outcome of COVID-19 patients admitted to the ICU is poor. In
a recent series of 1581 Italian patients with COVID-19 ARDS admitted
to ICU (88% requiring mechanical ventilation), with a median follow
up of 9 days, 26% have died and only 16% had been discharged [36].
In another series of patients with longer median follow-up (19 days),
one third of them (31%) have been discharged from ICU and 23% have
died [37]. In our series, with a median follow-up of 16 days, mortality
rate was 15%, while seven patients (53%) had been extubated and dis-
charged from ICU and two additional patients were improving.
One of the most relevant findings of our work is the lack of
adverse events associated with cell administration in these extremely
critical patients with respiratory insufficiency, massive inflammation
and prothrombotic risk. Safety of MSC treatments administered intra-
venously has been well demonstrated in multiple clinical trials for
different conditions (e.g. Crohn’s disease, graft-versus-host disease,
etc.) as reported in twometa-analyses including almost 3000 patients
[38,39]. Pre-clinical evidence of the potential for MSCs in viral lung
infections is still scarce and, in some cases, controversial [22,40]. It is
true that there are no preclinical studies in animal models of SARS-
CoV-2 infection and that most preclinical evidence comes from influ-
enza virus infection models, where the pathophysiology and systemic
manifestations are different. Nevertheless, although results of these
studies are not uniformly positive, no adverse events related to cell
therapy in this setting has been reported [22,40]. Stromal cells havebeen employed at the clinical level in other instances of severe pul-
monary disease induced by viral infection [41]. In this regard, men-
strual-blood derived MSCs were administered in 17 Chinese patients
H7N9-induced ARDS patients during the 20132014 outbreak, again
with no associated toxicity and a better survival compared to a con-
trol group of 44 patients (82.4% versus 45.4%) [42]. However, cases of
secondary concomitant or subsequent bacterial or fungal infection
after cell administration merit further comment. Although in patients
with COVID-19 under mechanical ventilation the risk of bacterial or
fungal secondary infection has been described to be around 8% and
its diagnosis is challenging [4345], theoretically an anti-inflamma-
tory or immunomodulatory treatment such as MSC can potentially
increase this risk and should be monitored and strictly assessed and
followed in subsequent clinical trials.
The association between AT-MSC and a decrease in inflammatory
parameters also support the hypothesis that cell administration may
contribute to generate an inflammatory and immunomodulatory micro-
environment [24]. This fact is of particular relevance, since almost all the
patients included in our series had received steroids as well as tocilizu-
mab (some also with anakinra and/or siltuximab), without clinical
response. Unlike monoclonal antibodies that act only by blocking the
effect of a single interleukin (e.g. tocilizumab for IL-6 or anakinra for IL-
1) [46], AT-MSCs could act in the inflammatory microenvironment of
endothelial and alveolar damage by interacting with various targets,
releasing anti-inflammatory and anti-apoptotic molecules in a paracrine
fashion, and modulating the action of the hyper-activated immune sys-
tem, including macrophages, neutrophils and other cell types, and
improving endothelial function [24,47,48].
Patients with COVID-19 pneumonia have been described to suffer
from a pro-coagulant status and high levels of D-dimer have been
associated to poor prognosis [16,17,37]. Remarkably, we observed a
reduction of D-dimer 5 days after the first AT-MSC dose in most
patients, and none of the patients developed a thromboembolic
event, although mesenchymal cells preferentially home to the pul-
monary circulation after endovenous administration [49]. Because of
these pro-coagulant status patients with COVID-19 are routinely
treated with low-molecular weight heparin [50]. It is possible that
receiving prophylactic anticoagulant therapy may have contributed
to decrease the potential prothrombotic risk that might have been
induced by MSCs, but due to the sample size this should be further
8 F. Sanchez-Guijo et al. / EClinicalMedicine 25 (2020) 100454evaluated in subsequent studies before making a definite recommen-
dation for concomitant administration of low weight heparin in
patients with COVID-19 receiving AT-MSC.
Finally, although the sample size does not allow definitive conclu-
sions, our results suggest that treatment with AT-MSC early after
mechanical intubation might improve the outcome. This is also a
potentially useful fact to take into account for the design of random-
ized clinical trials such as our BALMYS-19 trial. In addition, we have
not found differences in patients treated with thawed versus fresh
cells due to the limited number of patients included. This issue, that
has been widely debated in the MSC field [51,52], should be also clar-
ified in future trials.
Additional limitations of our study, besides the sample size, are
related to the type of study (non-randomized case series) and to the
variability inherent in the previous treatments, the different time of
cell administration and the non-uniformity in the number of doses.
The favorable response in many patients cannot be exclusively attrib-
uted to the effect of the cells, since other concomitant treatments
were administered a few days before the cell administration and in a
varied pattern. This proof-of-concept study, which constitutes the
first case series of intubated COVID-19 patients treated with AT-MSC,
has been used to design a randomized phase II clinical trial with a
control arm that will provide better knowledge of the real scope of
the potential of this therapeutic approach in this clinical setting.
In summary, our preliminary results, indicate that MSC derived
from adipose tissue can be safely administered in critically ill patients
with COVID-19 pneumonia and that administration of AT-MSC was
followed by clinical improvement and changes in inflammatory and
immune populations, which suggest a potential biological effect of
the cells. These results have served as an initial proof of concept
(especially taking into account the health emergency we are
experiencing) for the design of a randomized, controlled phase 2 clin-
ical trial of treatment with AT-MSCs in patients with COVID-19
requiring mechanical ventilation (BALMYS-19-“BAttLe against CO
using MesenchYmal Stromal cells”-; EudraCT: 2020-001266-11; clin-
icaltrials.gov identifier NCT04348461). Our trial, as other potential
randomized trials with a control arm consisting of standard treat-
ment, will contribute to understanding the real potential of this cell-
based therapeutic strategy [35,53].
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